RecruitingPhase 2NCT06536166
Ruxolitinib Treatment in Inclusion Body Myositis
Studying Inclusion body myositis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Principal Investigator
- François Jérôme AUTHIER, PrAssistance Publique - Hôpitaux de Paris
- Intervention
- Ruxolitinib(drug)
- Enrollment
- 80 enrolled
- Eligibility
- 45 years · All sexes
- Timeline
- 2025 – 2028
Study locations (16)
- Hôpital Pellegrin - Tripode, CHU de Bordeaux, Bordeaux, France, France
- Hôpital Pierre Wertheimer, CHU de Lyon, Bron, France, France
- CHU Caen Normandie, Caen, France, France
- Hôpital Henri-Mondor, APHP, Créteil, France, France
- Hôpital Raymond Poincaré, APHP, Garches, France, France
- Hôpital Roger Salengro, CHU de Lille, Lille, France, France
- Hôpital Dupuytren, CHU de Limoges, Limoges, France, France
- Hôpital de la Timone, APHM, Marseille, France, France
- CHU Nancy, Nancy, France, France
- Hôtel-Dieu, CHU Nantes, Nantes, France, France
- Hôpital Pasteur, CHU de Nice, Nice, France, France
- Hôpital Pitié-Salpêtrière, APHP, Paris, France, France
- Hôpital Christian Cabrol, CHU Reims, Reims, France, France
- Hôpital Bellevue, CHU Saint-Etienne, Saint-Etienne, France, France
- Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, France
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06536166 on ClinicalTrials.govOther trials for Inclusion body myositis
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNANCT07072676The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.LMU Klinikum
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT06450886Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body MyositisAbcuro, Inc.
- RECRUITINGEARLY PHASE1NCT06479863Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body MyositisAustin Neuromuscular Center
- ACTIVE NOT RECRUITINGNCT06153108Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over TimeUniversity of Kansas Medical Center
- ACTIVE NOT RECRUITINGPHASE3NCT04789070Phase III Trial of Sirolimus in IBMUniversity of Kansas Medical Center
- ACTIVE NOT RECRUITINGNCT05046821Sporadic Inclusion Body Myositis Natural History StudyUniversity of California, Irvine